This assertion came from Bharath Biotech, after Brazil indicated suspension of its contract with the Hyderabad-based vaccine maker after allegations of irregularities in the deal surfaced.
The supplies of Covaxin will be prioritised for public market through direct procurement by Brazil government while the supplies to private market would be based upon receipt of market authorisation from the country's regulator
